Published in J Agric Food Chem on November 15, 2006
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients | NCT05195918
Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. Evid Based Complement Alternat Med (2013) 1.13
Effect of pomegranate (Punica granatum) juice intake on hepatic oxidative stress. Eur J Nutr (2007) 1.10
Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila) (2010) 1.00
Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis (2011) 0.97
Current nutraceuticals in the management of osteoarthritis: a review. Ther Adv Musculoskelet Dis (2012) 0.94
Anti-inflammatory effects of ellagic acid on acute lung injury induced by acid in mice. Mediators Inflamm (2013) 0.90
Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med (2013) 0.88
Ellagitannins of the fruit rind of pomegranate (Punica granatum) antagonize in vitro the host inflammatory response mechanisms involved in the onset of malaria. Malar J (2010) 0.87
Influence of the solvents on the extraction of major phenolic compounds (punicalagin, ellagic acid and gallic acid) and their antioxidant activities in pomegranate aril. J Food Sci Technol (2014) 0.84
Protective effects of pomegranate (Punica granatum) juice on testes against carbon tetrachloride intoxication in rats. BMC Complement Altern Med (2014) 0.83
Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. Oxid Med Cell Longev (2015) 0.83
Efficacy and safety of pomegranate medicinal products for cancer. Evid Based Complement Alternat Med (2015) 0.81
Pomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth via Distinct Effects on Cell Cycle Control and Apoptosis. Evid Based Complement Alternat Med (2013) 0.81
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. Nutrients (2016) 0.80
Inhibition of nonenzymatic protein glycation by pomegranate and other fruit juices. J Med Food (2014) 0.79
Gut Microbiota Conversion of Dietary Ellagic Acid into Bioactive Phytoceutical Urolithin A Inhibits Heme Peroxidases. PLoS One (2016) 0.79
Pomegranate extracts and cancer prevention: molecular and cellular activities. Anticancer Agents Med Chem (2013) 0.79
The effects of proresolution of ellagic acid in an experimental model of allergic airway inflammation. Mediators Inflamm (2013) 0.77
Intake of polyphenol-rich pomegranate pure juice influences urinary glucocorticoids, blood pressure and homeostasis model assessment of insulin resistance in human volunteers. J Nutr Sci (2012) 0.76
A targeted approach for evaluating preclinical activity of botanical extracts for support of bone health. J Nutr Sci (2014) 0.76
Pomegranate Supplementation Protects against Memory Dysfunction after Heart Surgery: A Pilot Study. Evid Based Complement Alternat Med (2013) 0.76
Inhibitory effect of a standardized pomegranate fruit extract on Wnt signalling in 1, 2-dimethylhydrazine induced rat colon carcinogenesis. Dig Dis Sci (2013) 0.76
Ellagic acid inhibits melanoma growth in vitro. Dermatol Reports (2011) 0.75
In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepaten(®) Formulation. Nutrients (2015) 0.75
Comparative Evaluation of Antimicrobial Activity of Pomegranate-Containing Mouthwash Against Oral-Biofilm Forming Organisms: An Invitro Microbial Study. J Clin Diagn Res (2016) 0.75
Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine. Sci Rep (2017) 0.75
Matrix effects on the stability and antioxidant activity of red cabbage anthocyanins under simulated gastrointestinal digestion. Biomed Res Int (2014) 0.75
Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines. Cent Eur J Immunol (2017) 0.75
Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and Mechanisms. Adv Nutr (2016) 0.75
Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. J Clin Invest (2017) 0.75
Amalaki rasayana, a traditional Indian drug enhances cardiac mitochondrial and contractile functions and improves cardiac function in rats with hypertrophy. Sci Rep (2017) 0.75
Potential Antitumor Effects of Pomegranates and Its Ingredients. Pharmacogn Rev (2017) 0.75
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci (2010) 1.37
How important are gender differences in pharmacokinetics? Clin Pharmacokinet (2002) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet (2010) 1.25
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med (2008) 1.20
Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16
Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther (2005) 1.14
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents (2006) 1.13
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother (2006) 1.12
Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents (2005) 1.11
Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11
Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am (2005) 1.07
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07
Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci (2002) 1.06
Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol (2003) 1.05
Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine (2002) 1.04
Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents (2012) 1.03
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents (2010) 1.03
Safety assessment of pomegranate fruit extract: acute and subchronic toxicity studies. Food Chem Toxicol (2008) 1.02
Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol (2003) 1.02
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents (2005) 1.02
Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers. J Agric Food Chem (2008) 1.01
Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents (2009) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother (2009) 0.98
Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol (2010) 0.98
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother (2007) 0.98
PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol (2008) 0.98
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv (2011) 0.97
Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol (2011) 0.97
Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet (2009) 0.96
Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol (2004) 0.96
Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol (2008) 0.96
Protective effects of standardized pomegranate (Punica granatum L.) polyphenolic extract in ultraviolet-irradiated human skin fibroblasts. J Agric Food Chem (2008) 0.96
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol (2011) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Interstitial tissue concentrations of cefpodoxime. J Antimicrob Chemother (2002) 0.93
How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc (2004) 0.93
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol (2013) 0.93
Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res (2010) 0.93
The Candida albicans phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. Microbiology (2008) 0.93
Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem (2006) 0.93
A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int J Antimicrob Agents (2008) 0.92
Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion (2009) 0.92
The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia. Blood (2004) 0.91
Grapefruit-medication interactions. CMAJ (2013) 0.91
Physiological, pharmacokinetic, and pharmacodynamic changes in space. J Clin Pharmacol (2004) 0.91
Single- and multiple-dose pharmacokinetics of oral creatine. J Clin Pharmacol (2003) 0.91
Antimicrobial tissue concentrations. Infect Dis Clin North Am (2003) 0.91
Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother (2006) 0.90
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents (2009) 0.89
Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol (2005) 0.88
Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography. Antimicrob Agents Chemother (2007) 0.88
Systemic availability and pharmacokinetics of thymol in humans. J Clin Pharmacol (2002) 0.87
Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci (2010) 0.87
Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn (2013) 0.86
The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion (2010) 0.86
Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents (2009) 0.85
Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. Pharmacol Biochem Behav (2010) 0.85
Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.85
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother (2009) 0.85
Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents (2008) 0.85
Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J Pharmacokinet Pharmacodyn (2006) 0.84
Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol (2005) 0.84
Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations. Planta Med (2012) 0.84
Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J Clin Pharmacol (2010) 0.83
Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. Ther Clin Risk Manag (2010) 0.83
Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thromb Haemost (2005) 0.83
Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci (2005) 0.83
Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood (2003) 0.83
Model-based drug approval - the rubber hits the road. Int J Clin Pharmacol Ther (2012) 0.82
A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost (2010) 0.81
Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone. AAPS J (2008) 0.81
In vitro microdialysis sampling of docetaxel. J Pharm Biomed Anal (2004) 0.81
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. Chest (2008) 0.81
Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.81
Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. J Clin Pharmacol (2003) 0.81
Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci (2007) 0.81
When is protein binding important? J Pharm Sci (2013) 0.81
Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. Antimicrob Agents Chemother (2013) 0.81
Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med (2004) 0.81
A novel breath test to directly measure use of vaginal gel and condoms. AIDS Behav (2013) 0.80
Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily. Antimicrob Agents Chemother (2013) 0.80